CXCR4 and Familial prostate cancer: The endpoint tumors treated with combination therapy were still a modest 210 mm3 on average compared to nearly 480 mm3 for Taxotere alone suggesting that treatment with CXCR4 antagonists directed against progenitor cells may be useful in combination with conventional drugs in prostate cancer treatment.